School of Medicine

Showing 1-10 of 33 Results

  • Agnieszka Kalinowski

    Agnieszka Kalinowski

    Clinical Instructor, Psychiatry and Behavioral Sciences

    Bio I am a translational physician-scientist focused on studying the role of the immune system in patients with schizophrenia. My work spans careful clinical characterization of patients to understanding mechanisms in basic science model systems, allowing to provide mechanistic understanding to observations in clinical samples. Currently, I'm focused on deciphering the role of the complement system and how the known genetic risk translates into pathophysiological disease mechanisms. I hope that this work will pave the way to novel treatment strategies.

  • Katherine Kaplan

    Katherine Kaplan

    Clinical Instructor, Psychiatry and Behavioral Sciences

    Current Research and Scholarly Interests Dr. Kaplan's research interests span four (often overlapping) domains: (1) pathophysiologic aspects of insomnia and hypersomnia in mood disorders, including mechanisms, correlates, and sequelae of these sleep disturbances; (2) behavioral interventions for sleep disturbances in adults and adolescents; (3) circadian and psychosocial factors impacting sleep in adolescence; and (4) machine learning approaches to big data.

  • Makoto Kawai

    Makoto Kawai

    Clinical Associate Professor, Psychiatry and Behavioral Sciences - Stanford Center for Sleep Sciences and Medicine

    Bio I am a physician scientist in the field of sleep medicine in aging and brain function. Using combined polysomnogram and novel neuroimaging technology, I aim to identify potential sleep biomarkers to investigate the mechanism of progression from normal aging to Mild Cognitive Impairment (MCI) or dementia. I also investigate the impact of sleep on cognitive/affective function or behavior abnormality in various neurodevelopmental and neurodegenerative disorders.

  • Debra Lee Kaysen

    Debra Lee Kaysen

    Professor of Psychiatry and Behavioral Sciences (Public Mental Health & Population Sciences) at the Stanford University Medical Center

    Bio Debra Kaysen received her PhD in Clinical Psychology from the University of Missouri. She completed an internship at the University of Washington and continued there to complete an NIAAA-funded F32 to study the area of overlap between PTSD and alcohol use disorders. Dr. Kaysen joined the faculty at University of Washington in 2006 in the Department of Psychiatry and Behavioral Sciences. While there she founded a program to develop and test more accessible interventions for individuals suffering from mental health symptoms following traumatic events. Dr. Kaysen joined the Stanford faculty in 2019.

    Dr. Kaysen’s area of specialty both in research and clinical work is in treatment for those who have experienced traumatic events including treatment of PTSD and related disorders. She has conducted critical studies on treatment of PTSD and/or substance use across a variety of populations (sexual minority women, Native Americans, sexual assault survivors, torture survivors, active duty military) and in a variety of settings (the Democratic Republic of Congo, Iraq, primary care, rural settings). Other research conducted by Dr. Kaysen has focused on increasing our understanding of how PTSD and substance use may influence each other. Dr. Kaysen is currently the President of the International Society for Traumatic Stress Studies ( Her research has been funded by the National Institute of Alcohol Abuse and Alcoholism, the National Institute of Drug Abuse, the National Institute on Minority Health and Health Disparities, the Department of Defense, PCORI, and USAID.

    Dr. Kaysen is currently involved in helping develop and implement coping strategies for healthcare workers dealing with mental health concerns related to COVID-19. Dr. Kaysen's clinical work has been featured on This American Life (

  • Corey Keller, MD, PhD

    Corey Keller, MD, PhD

    Assistant Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences) at the Palo Alto Veterans Affairs Health Care System

    Current Research and Scholarly Interests The overarching goal of my research is to identify and apply individualized stimulation protocols to elicit precise and predictable long-term plasticity in order to alleviate psychiatric suffering. Repetitive transcranial magnetic stimulation (TMS) was FDA approved for treatment-resistant depression over 10 years ago as a circuit-based, targeted intervention that complements traditional psychiatric treatments. Remission rates, however, remain at 15% at worst and 40% at best. TMS trials using identical treatment settings are currently underway for bipolar disorder, PTSD, OCD, and addiction. The low efficacy and one-size-fits-all treatment (with respect to timing, site, and intensity) stems from our lack of understanding of how TMS induces brain changes. It is reasonable to expect that we can improve the efficacy of TMS. By selecting the optimal parameters based on the stimulation timing, location, intensity, and duration of the TMS pulses, we can customize treatment to maximize an individual’s clinical response. My 10 year research aims are to obtain this level of specificity and treatment response by:

    1) Developing an integrated translational clinical research program.
    2) Identifying the specific neural mechanisms underlying repetitive stimulation-induced plasticity.
    3) Creating novel treatments with TMS based on experimentally-driven computational models of plasticity.

    This three-pronged approach has the expected outcome of producing novel stimulation treatments with enhanced specificity, plasticity, and efficacy. By increasing our understanding of the underlying mechanism and monitoring of brain changes during TMS, we will markedly increase the utility of these powerful techniques. Together, this work will help transform interventional psychiatry from an isolated (from a clinic perspective), one-size-fits-all treatment approach to one that focuses on targeting objective biomarkers and that is collaborative, large-scale, and automated, pushing the field into the age of personalized neuromodulation.

Latest information on COVID-19